All Articles

Study determines that permanently discontinuing immune checkpoint inhibitors after grade ≥2 immune-related adverse events is an appropriate response for patients with stage IV non–small-cell lung cancer.

A review of multiple clinical trials in patients with non–small-cell lung cancer and brain metastases finds adagrasib effectively penetrates the central nervous system, resulting in good response rates.

Navigation researchers are recognized at the AONN+ Annual Conference for outstanding contributions to the field and to the navigation literature. It is our pleasure to present the 2022 Exceptional Research in Navigation Award winners!

American Indians (AIs) and Alaska Natives (ANs) are the only racial groups with documented, statistically significant geographic differences in cancer incidence, mortality, and survival compared with all other racial groups in the United States, according to Linda Burhansstipanov, MSPH, DrPH, member of the Cherokee Nation of Oklahoma and president of Native American Cancer Initiatives, Inc.

In 2022, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Adapting to the changes, societies such as the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, and European Society for Medical Oncology have adopted virtual and hybrid formats that deliver cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual and hybrid formats in terms of reach and impact, we are bringing the Year in Review series that seeks to disseminate key information on treatment advances to clinicians in a timely and effective manner.

Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer.

Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements.

The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers.

Final analysis of the phase 2 FIGHT-202 trial demonstrated durable response and a tolerable safety profile for pemigatinib in patients with metastatic cholangiocarcinoma.

Updated data from the TOPAZ-1 study revealed improved median overall survival for the full patient population and no new safety signals.